GlobeNewsWire
17 Sept 2026, 11:42 UTC · 3h ago
Verdict
Headline takes no side. We score CMND +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 2 new · 1 priced in
Clearmind Medicine's drug candidate MEAI has advanced to a Phase 2a clinical trial for the treatment of Alcohol Use Disorder.
Priced inno timing evidence provided for trial phase
So whatPhase 2a success is the primary catalyst for valuation re-rating before potential Phase 3 funding needs.
More positive than 91% of claims this week
Clearmind testified at an FDA hearing on September 14, 2026, regarding the future therapeutic use of psychedelic drugs.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Newannounced today, Sept 17, regarding Sept 14 event
So whatDirect FDA engagement on 'Patient Access' may lower the regulatory barrier for non-supervised dosing models in 2027.
More positive than 77% of claims this week
The company claims its non-hallucinogenic neuroplastogens may eliminate the need for expensive supervised dosing.
Newannounced today, Sept 17
More positive than 65% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
The company was invited by the FDA to provide expert testimony on psychedelic treatments and is progressing with Phase 2a clinical trials.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+16.6%
Price agrees with the score
$0.9400 vs $0.8059 close before publication (Sep 16) · not market-adjusted
CMND chart →
